Glucose metabolism in posterior cingulate cortex has supplementary value to predict the progression of cognitively unimpaired to dementia due to Alzheimer's disease: an exploratory study of 18F-FDG-PET

被引:6
作者
Zhang, Qi [1 ]
Fan, Chunqiu [2 ]
Wang, Luyao [3 ]
Li, Taoran [4 ]
Wang, Min [3 ]
Han, Ying [2 ,5 ,6 ,7 ]
Jiang, Jiehui [3 ,8 ]
机构
[1] Shanghai Univ, Sch Commun & Informat Engn, Shanghai 200444, Peoples R China
[2] Capital Med Univ, Dept Neurol, Xuanwu Hosp, Beijing 100053, Peoples R China
[3] Shanghai Univ, Sch Life Sci, Shanghai 200444, Peoples R China
[4] Nanjing Med Univ, Dept Gastroenterol, Affiliated Hosp 1, Nanjing 210029, Jiangsu, Peoples R China
[5] Hainan Univ, Sch Biomed Engn, Haikou 570228, Peoples R China
[6] Beijing Inst Brain Disorders, Ctr Alzheimers Dis, Beijing 100053, Peoples R China
[7] Natl Clin Res Ctr Geriatr Dis, Beijing 100053, Peoples R China
[8] Nucl Med & Mol Imaging Key Lab Sichuan Prov, Luzhou 646000, Sichuan, Peoples R China
基金
美国国家卫生研究院;
关键词
Cognitively unimpaired; FDG PET; Kaplan-Meier analysis; Neurodegeneration; Posterior cingulate cortex; ASSOCIATIONS; IMPAIRMENT; BIOMARKERS; DIAGNOSIS; FRAMEWORK; IMPROVES; DECLINE; TAU; FDG; CSF;
D O I
10.1007/s11357-023-00897-0
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Amyloid-ss (A ss) and tau are important biomarkers to predict the progression of cognitively unimpaired (CU) to dementia due to Alzheimer's disease (AD), according to the diagnosis framework from the US National Institute on Aging and the Alzheimer's Association (NIA-AA). However, it is clinically difficult to predict those subjects who were already with A ss positive (A +) or tau positive (T +). As a typical characteristic of neurodegeneration in the diagnosis framework, the hypometabolism of the posterior cingulate cortex (PCC) has significant clinical value in the early prediction and prevention of AD. In this paper, we proposed the glucose metabolism in the PCC as a biomarker supplement to A ss and tau biomarkers. First, we calculated the standard uptake value ratio (SUVR) of PCC based on fluorodeoxyglucose positron emission computed tomography (FDG PET) imaging. Secondly, we performed Kaplan-Meier (KM) survival analyses to explore the predictive performance of PCC SUVR, and the hazard ratio (HR) was calculated. Finally, we performed Pearson correlation analyses to explore the physiological significance of PCC SUVR. As a result, the PCC SUVR showed a consistent downward trend along the AD continuum. KM analyses showed better predictive performance when we combined PCC SUVR with cerebro-spinal fluid (CSF) A ss(42) (from HR= 2.56 to 3.00 within 5 years; from HR = 2.76 to 4.20 within 10 years) and ptau-181 (from 2.83 to 3.91 within 5 years; from HR = 2.32 to 4.17 within 10 years). There was a slight correlation between A ss(42)/A ss(40) and PCC SUVR (r = 0.14, p = 0.02). In addition, several cognition scales were also correlated to PCC SUVR (from r = -0.407 to 0.383, p < 0.05). Our results showed that glucose metabolism in PCC may be a potential biomarker supplement to the A ss and tau biomarkers to predict the progression of CU to AD.
引用
收藏
页码:1407 / 1420
页数:14
相关论文
共 36 条
  • [1] Correlations between kynurenines in plasma and CSF, and their relation to markers of Alzheimer's disease pathology
    Bakker, Lieke
    Kohler, Sebastian
    Eussen, Simone J. P. M.
    Choe, Kyonghwan
    van den Hove, Daniel L. A.
    Kenis, Gunter
    Rutten, Bart P. F.
    Ulvik, Arve
    Ueland, Per M.
    Verhey, Frans R. J.
    Ramakers, Inez H. G. B.
    [J]. BRAIN BEHAVIOR AND IMMUNITY, 2023, 111 : 312 - 319
  • [2] Longitudinal stability of CSF biomarkers in Alzheimer's disease
    Blennow, Kaj
    Zetterberg, Henrik
    Minthon, Lennart
    Lannfelt, Lars
    Strid, Stig
    Annas, Peter
    Basun, Hans
    Andreasen, Niels
    [J]. NEUROSCIENCE LETTERS, 2007, 419 (01) : 18 - 22
  • [3] Neuropsychological Criteria for Mild Cognitive Impairment Improves Diagnostic Precision, Biomarker Associations, and Progression Rates
    Bondi, Mark W.
    Edmonds, Emily C.
    Jak, Amy J.
    Clark, Lindsay R.
    Delano-Wood, Lisa
    McDonald, Carrie R.
    Nation, Daniel A.
    Libon, David J.
    Au, Rhoda
    Galasko, Douglas
    Salmon, David P.
    [J]. JOURNAL OF ALZHEIMERS DISEASE, 2014, 42 (01) : 275 - 289
  • [4] Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease
    Brier, Matthew R.
    Gordon, Brian
    Friedrichsen, Karl
    McCarthy, John
    Stern, Ari
    Christensen, Jon
    Owen, Christopher
    Aldea, Patricia
    Su, Yi
    Hassenstab, Jason
    Cairns, Nigel J.
    Holtzman, David M.
    Fagan, Anne M.
    Morris, John C.
    Benzinger, Tammie L. S.
    Ances, Beau M.
    [J]. SCIENCE TRANSLATIONAL MEDICINE, 2016, 8 (338)
  • [5] Brain metabolic correlates of CSF Tau protein in a large cohort of Alzheimer's disease patients: A CSF and FDG PET study
    Chiaravalloti, Agostino
    Barbagallo, Gaetano
    Ricci, Maria
    Martorana, Alessandro
    Ursini, Francesco
    Sannino, Pasqualina
    Karalis, Georgios
    Schillaci, Orazio
    [J]. BRAIN RESEARCH, 2018, 1678 : 116 - 122
  • [6] Neuronal dysfunction and disconnection of cortical hubs in non-demented subjects with elevated amyloid burden
    Drzezga, Alexander
    Becker, J. Alex
    Van Dijk, Koene R. A.
    Sreenivasan, Aishwarya
    Talukdar, Tanveer
    Sullivan, Caroline
    Schultz, Aaron P.
    Sepulcre, Jorge
    Putcha, Deepti
    Greve, Doug
    Johnson, Keith A.
    Sperling, Reisa A.
    [J]. BRAIN, 2011, 134 : 1635 - 1646
  • [7] Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group
    Dubois, Bruno
    Villain, Nicolas
    Frisoni, Giovanni B.
    Rabinovici, Gil D.
    Sabbagh, Marwan
    Cappa, Stefano
    Bejanin, Alexandre
    Bombois, Stephanie
    Epelbaum, Stephane
    Teichmann, Marc
    Habert, Marie-Odile
    Nordberg, Agneta
    Blennow, Kaj
    Galasko, Douglas
    Stern, Yaakov
    Rowe, Christopher C.
    Salloway, Stephen
    Schneider, Lon S.
    Cummings, Jeffrey L.
    Feldman, Howard H.
    [J]. LANCET NEUROLOGY, 2021, 20 (06) : 484 - 496
  • [8] The measurement of everyday cognition: Development and validation of a short form of the Everyday Cognition scales
    Farias, Sarah Tomaszewski
    Mungas, Dan
    Harvey, Danielle J.
    Simmons, Amanda
    Reed, Bruce R.
    DeCarli, Charles
    [J]. ALZHEIMERS & DEMENTIA, 2011, 7 (06) : 593 - 601
  • [9] CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts
    Hansson, Oskar
    Seibyl, John
    Stomrud, Erik
    Zetterberg, Henrik
    Trojanowski, John Q.
    Bittner, Tobias
    Lifke, Valeria
    Corradini, Veronika
    Eichenlaub, Udo
    Batrla, Richard
    Buck, Katharina
    Zink, Katharina
    Rabe, Christina
    Blennow, Kaj
    Shaw, Leslie M.
    [J]. ALZHEIMERS & DEMENTIA, 2018, 14 (11) : 1470 - 1481
  • [10] Huda Aulia, 2017, World J Nucl Med, V16, P108, DOI 10.4103/1450-1147.203075